Alto Neuroscience

United States
Medford, Wisconsin, United States, 94022

Company profile

Alto Neuroscience company profile

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2019-01-01, Year

Headquarters

Postal code
94022
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
12
Total equity funding
$254.3M
Last funding
Post IPO Equity / $50M / 2025-10-20
Last equity funding
Post IPO Equity / $50M
Investors
34
Lead investors
9
Founders
3
Articles
360
Exited on
2024-02-02

Founders and investors

Founders

Amit EtkinDan SegalWei Wu

Lead investors

Alkeon CapitalAlpha Wave VenturesApeiron Investment GroupInVivium CapitalK2 HealthVenturesLightswitch CapitalPerceptive AdvisorsTim KendallWellcome Trust

Investors

Eli LillyFranklin TempletonGaingelsValor Equity PartnersVivo Capital